LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended …
Author: Business Wire
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
PARSIPPANY, N.J.–(BUSINESS WIRE)–Pravin U. Dugel, M.D., President, will participate in a panel discussion at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Alcon Reports Second Quarter 2022 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Second Quarter 2022 Results
Alcon Reports Second Quarter 2022 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Second Quarter 2022 Results
Harrow Health Announces Second Quarter 2022 Financial Results
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (NASDAQ: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced results f…
iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for 510K Clearance
NEW YORK–(BUSINESS WIRE)– #AI–iHealthScreen Inc. completed a prospective study for early diagnosis of AMD in primary care settings. The initial clinical trial results show adequate accuracy for FDA clearance. The study was funded by NIH SBIR grants …
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today r…
Global Optical Disorders Drugs Market Report 2022: Increasing Prevalence of Age-Related Macular Degeneration Expected to Drive Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Disorders Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027” report has been added to ResearchAndMarkets.com’s offering. The report on the global optical disorders drugs market p…
China Aflibercept Market Investigation Report 2022-2031 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Aflibercept Market 2022-2031” report has been added to ResearchAndMarkets.com’s offering. Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration …
LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
Global Eyewear Market to Reach $323.77 Billion by 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eyewear Market Size, Share & Trends Analysis Report by Product (Contact Lenses, Spectacles, Sunglasses), by Distribution Channel, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAnd…
Resumen: Illumina Ventures anuncia la ampliación de su equipo en Europa
SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, empresa de capital de riesgo centrada en la atención sanitaria y gestionada de forma independiente, en asociación estratégica con Illumina (NASDAQ: ILMN), ha anunciado hoy la incorporación de cuatro nu…
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and fi…
Illumina Ventures annonce l’expansion de son équipe Europe
SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, société de capital-risque indépendante axée sur les soins de santé dans le cadre d’un partenariat stratégique avec Illumina (NASDAQ : ILMN), a annoncé aujourd’hui l’ajout de quatre nouveaux membres à s…
Illumina Ventures gibt Erweiterung seines Europa-Teams bekannt
SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, eine unabhängig verwaltete, auf das Gesundheitswesen ausgerichtete Risikofirma in einer strategischen Partnerschaft mit Illumina (NASDAQ: ILMN), teilte heute die Aufnahme von vier neuen Mitgliedern in …
Riassunto: Illumina Ventures annuncia l’ampliamento del suo team europeo
SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, una società di venture capital autonoma operante nel settore sanitario che intrattiene un rapporto di collaborazione strategica con Illumina (NASDAQ: ILMN), ha annunciato in data odierna l’aggiunta di …
Samenvatting: Illumina Ventures kondigt uitbreiding van haar Europa-team aan
SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, een onafhankelijk geleide, op de gezondheidszorg gerichte onderneming in een strategisch partnerschap met Illumina (NASDAQ: ILMN), heeft vandaag de toevoeging van vier nieuwe leden aan haar Europese te…
Illumina Ventures Announces Expansion of its Europe Team
SAN FRANCISCO–(BUSINESS WIRE)–Illumina Ventures, a healthcare-focused venture firm partnered with Illumina, announces the addition of four new members to its European team.
NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market close on Thursday, August 11, 2022 and will hold an i…